A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2022 Mar 24

PMID 35321497

Authors

Nada A Ashour

Ayman Abo Elmaaty

Amany A Sarhan

Eslam B Elkaeed

Ahmed M Moussa

Ibrahim Ali Erfan

Ahmed A Al-Karmalawy

Affiliations

Soon will be listed here.

Abstract

The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some specific FDA-approved drugs have already been repurposed and authorized for COVID-19 treatment. The repurposed drugs used were either antiviral or non-antiviral drugs. Accordingly, the present review thoroughly focuses on the repurposing efficacy of these drugs including clinical trials experienced, the combination therapies used, the novel methods followed for treatment, and their future perspective. Therefore, drug repurposing was regarded as an effective avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On the other hand, PF-07321332 is an oral antiviral drug developed by Pfizer. For the treatment of COVID-19, the PF-07321332/ritonavir combination medication is used in Phase III studies and was marketed as Paxlovid. Herein, we represented the almost history of combating COVID-19 from repurposing to the recently available oral anti-SARS-CoV-2 candidates, as a new hope to end the current pandemic.

Citing Articles

Lipid-encapsulated gold nanoparticles: an advanced strategy for attenuating the inflammatory response in SARS-CoV-2 infection.

Dhandapani S, Ha Y, Wang R, Kwon T, Cho I, Kim Y J Nanobiotechnology. 2025; 23(1):15.

PMID: 39815303 PMC: 11734238. DOI: 10.1186/s12951-024-03064-5.

Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.

Ghasemiyeh P, Mohammadi-Samani S Virol J. 2024; 21(1):98.

PMID: 38671455 PMC: 11055380. DOI: 10.1186/s12985-024-02370-6.

Machine learning coupled with causal inference to identify COVID-19 related chemicals that pose a high concern to drinking water.

Han M, Liang J, Jin B, Wang Z, Wu W, Arp H iScience. 2024; 27(2):109012.

PMID: 38352231 PMC: 10863329. DOI: 10.1016/j.isci.2024.109012.

Sulfated liposome-based artificial cell membrane glycocalyx nanodecoys for coronavirus inactivation by membrane fusion.

Li X, Cheng N, Shi D, Li Y, Li C, Zhu M Bioact Mater. 2023; 33:1-13.

PMID: 38024234 PMC: 10660003. DOI: 10.1016/j.bioactmat.2023.10.021.

Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors.

Mushebenge A, Ugbaja S, Mbatha N, Khan R, Kumalo H Int J Mol Sci. 2023; 24(21).

PMID: 37958503 PMC: 10647470. DOI: 10.3390/ijms242115518.

References

Liu X, Wang X . Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020; 47(2):119-121. PMC: 7128649. DOI: 10.1016/j.jgg.2020.02.001. View

Farne H, Kumar K, Ritchie A, Finney L, Johnston S, Singanayagam A . Repurposing Existing Drugs for the Treatment of COVID-19. Ann Am Thorac Soc. 2020; 17(10):1186-1194. PMC: 7640626. DOI: 10.1513/AnnalsATS.202005-566FR. View

Ali M, Hanif M, Haider M, Ahmed M, Sundas F, Hirani A . Treatment Options for COVID-19: A Review. Front Med (Lausanne). 2020; 7:480. PMC: 7412857. DOI: 10.3389/fmed.2020.00480. View

Mahmoud D, Ismail W, Moatasim Y, Kutkat O, ElMeshad A, Ezzat S . Delineating a potent antiviral activity of extract loaded nano-formulation against SARS-CoV-2: studies. J Drug Deliv Sci Technol. 2021; 66:102845. PMC: 8440321. DOI: 10.1016/j.jddst.2021.102845. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Hilgenfeld R . From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014; 281(18):4085-96. PMC: 7163996. DOI: 10.1111/febs.12936. View

Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H . Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005; 40(3):374-80. DOI: 10.1086/427283. View

Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M . A global treatments for coronaviruses including COVID-19. J Cell Physiol. 2020; 235(12):9133-9142. PMC: 7273044. DOI: 10.1002/jcp.29785. View

Pouya M, Afshani S, Salek Maghsoudi A, Hassani S, Mirnia K . Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. Daru. 2020; 28(2):745-764. PMC: 7391927. DOI: 10.1007/s40199-020-00359-4. View

10.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

11.

Cao Y, Deng Q, Dai S . Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020; 35:101647. PMC: 7151266. DOI: 10.1016/j.tmaid.2020.101647. View

12.

Muller A, Cadenas E, Graf P, Sies H . A novel biologically active seleno-organic compound--I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol. 1984; 33(20):3235-9. DOI: 10.1016/0006-2952(84)90083-2. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

Li F, Michelson A, Foraker R, Zhan M, Payne P . Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2. BMC Med Inform Decis Mak. 2021; 21(1):15. PMC: 7789899. DOI: 10.1186/s12911-020-01373-x. View

15.

Malin J, Suarez I, Priesner V, Fatkenheuer G, Rybniker J . Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. 2020; 34(1). PMC: 7566896. DOI: 10.1128/CMR.00162-20. View

16.

El Gizawy H, Boshra S, Mostafa A, Mahmoud S, Ismail M, Alsfouk A . (L.) Merr. Bioactive Constituents Exert Anti-SARS-CoV-2 and Anti-Inflammatory Activities: Molecular Docking and Dynamics, In Vitro, and In Vivo Studies. Molecules. 2021; 26(19). PMC: 8510437. DOI: 10.3390/molecules26195844. View

17.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

18.

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

19.

Wei L, Shang J, Ma Y, Xu X, Huang Y, Guan Y . Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. J Clin Transl Hepatol. 2019; 7(3):221-225. PMC: 6783684. DOI: 10.14218/JCTH.2019.00018. View

20.

Li Z, Wang Y, Zhu J, Zhang Y, Zhang W, Zhou M . Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona. J Control Release. 2020; 320:1-18. DOI: 10.1016/j.jconrel.2020.01.007. View